AGMB-447
Not Specified
Not DisclosedActive
Key Facts
About Agomab Therapeutics
Agomab Therapeutics is building a company focused on treating fibrosis by translating deep expertise in growth factor biology into a pipeline of modulating candidates. Its mission is to develop disease-modifying therapeutics that aim to resolve fibrosis and restore organ function. The company's lead candidate, Ontunisertib (AGMB-129), is in Phase 1 development for fibrostenotic Crohn's disease, supported by a strong leadership team and recent IPO proceeds of approximately $200 million. Agomab's strategy combines internal scientific and development expertise with external partnerships to address pressing medical needs in fibrotic diseases.
View full company profileTherapeutic Areas
Other Not Specified Drugs
| Drug | Company | Phase |
|---|---|---|
| Inflammation Programs | Arcus Biosciences | Not Specified |
| Bone Marrow Conditioning Program | Telix Pharmaceuticals | Pipeline |
| AGMB-101 | Agomab Therapeutics | Not Disclosed |
| TRIFERTY-ATM® | Laboratorio Reig Jofre | Approved/Commercial |
| AGEN1571 (anti-ILT2) | Agenus | Not specified |
| AGEN1777 | Agenus | Not specified |
| AGEN1721 | Agenus | Not specified |
| INCAGN1876 (GITR Agonist) | Agenus | Not specified |
| INCAGN1949 (OX40 Agonist) | Agenus | Not specified |
| AGEN1327 (anti-TIGIT) | Agenus | Not specified |
| AGEN2373 (CD137 Agonist) | Agenus | Not specified |
| AGENT-797 (iNKT Cell Therapy) | Agenus | Not specified |